Neurocompute scores pediatric oncology literature, surfaces overlooked therapeutic signals, and turns fragmented childhood cancer research into a living discovery terminal.
A grade PMID 42321916
View analysis →A grade PMID 42372741
View analysis →A grade PMID 42216567
View analysis →A grade PMID 41916649
View analysis →A grade PMID 42382416
View analysis →A grade PMID 42150584
View analysis →A grade PMID 41756844
View analysis →A grade PMID 42362103
View analysis →A grade PMID 42101908
View analysis →A grade PMID 42248607
View analysis →A grade PMID 41667193
View analysis →A grade PMID 42260111
View analysis →In this adult randomised phase 2 trial of unresectable hepatocellular carcinoma, adding low-dose ipilimumab to first-line atezolizumab plus bevacizumab failed to meet the prespecified response threshold and was associated with six treatment-related deaths versus none with the doublet.
The trial provides evidence against adding ipilimumab 1 mg/kg to atezolizumab plus bevacizumab in the studied adult first-line HCC population; any inference that this result should guide pediatric liver-tumor treatment would be unsupported because no pediatric patients or pediatric-specific tumor biology were evaluated.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 96.2/100. Study design: 100.0; human relevance: 100.0; therapeutic relevance: 96.0; sample size: 70.0; recency: 100.0; abstract quality: 100.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 96.0/100. Study design: 100.0; human relevance: 100.0; therapeutic relevance: 100.0; sample size: 60.0; recency: 100.0; abstract quality: 100.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 94.0/100. Study design: 90.0; human relevance: 100.0; therapeutic relevance: 100.0; sample size: 70.0; recency: 100.0; abstract quality: 100.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 94.0/100. Study design: 90.0; human relevance: 100.0; therapeutic relevance: 100.0; sample size: 80.0; recency: 90.0; abstract quality: 100.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 93.8/100. Study design: 90.0; human relevance: 100.0; therapeutic relevance: 94.0; sample size: 90.0; recency: 90.0; abstract quality: 100.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 93.4/100. Study design: 100.0; human relevance: 100.0; therapeutic relevance: 91.9; sample size: 60.0; recency: 90.0; abstract quality: 100.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 93.4/100. Study design: 100.0; human relevance: 100.0; therapeutic relevance: 81.9; sample size: 80.0; recency: 90.0; abstract quality: 100.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 93.0/100. Study design: 90.0; human relevance: 100.0; therapeutic relevance: 95.1; sample size: 70.0; recency: 100.0; abstract quality: 100.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 93.0/100. Study design: 90.0; human relevance: 100.0; therapeutic relevance: 100.0; sample size: 60.0; recency: 100.0; abstract quality: 100.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 92.7/100. Study design: 100.0; human relevance: 100.0; therapeutic relevance: 93.7; sample size: 50.0; recency: 90.0; abstract quality: 100.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 92.5/100. Study design: 90.0; human relevance: 100.0; therapeutic relevance: 95.2; sample size: 80.0; recency: 100.0; abstract quality: 85.0.
